Transcription Elongation Regulator 1 Is a Co-integrator of the Cell Fate Determination Factor Dachshund Homolog 1*

From the Departments of *Cancer Biology and **Stem Cell Biology and Regenerative Medicine, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, the †Department of Molecular Biology, Instituto de Parasitología y Biomedicina "López Neyra," Consejo Superior de Investigaciones Científicas, 18100 Granada, Spain, the **Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York 10461, and the ¶Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, China.

DACH1 (Dachshund homolog 1) is a key component of the retinal determination gene network and regulates gene expression either indirectly as a co-integrator or through direct DNA binding. The current studies were conducted to understand, at a higher level of resolution, the mechanisms governing DACH1-mediated transcriptional repression via DNA sequence-specific binding. DACH1 repressed gene transcription driven by the DACH1-responsive element (DRE). Recent genome-wide ChIP-Seq analysis demonstrated DACH1 binding sites co-localized with Forkhead protein (FOX) binding sites. Herein, DACH1 repressed, whereas FOX proteins enhanced, both DRE and FOXA-responsive element-driven gene expression. Reduced DACH1 expression using a shRNA approach enhanced FOX protein activity. As DACH1 antagonized FOX target gene expression and attenuated FOX signaling, we sought to identify limiting co-integrator proteins governing DACH1 signaling. Proteomic analysis identified transcription elongation regulator 1 (TCERG1) as the transcriptional co-regulator of DACH1 activity. The FF2 domain of TCERG1 was required for DACH1 binding, and the deletion of FF2 abolished DACH1 trans-repression function. The carboxyl terminus of DACH1 was necessary and sufficient for TCERG1 binding. Thus, DACH1 represses gene transcription through direct DNA binding to the promoter region of target genes by recruiting the transcriptional co-regulator, TCERG1.

Development of the compound eye in Drosophila is tightly regulated by the retinal determination gene network (RDGN), which includes a number of proteins encoded by genes such as twin of eyeless (toy), eyeless (ey), sine oculis (so), and eyes absent (eya) (1). The Dachshund (dac) gene was originally cloned as a dominant inhibitor of ellipse. Genetic deletion of dac causes eye- and wing-specific defects in Drosophila (2). Ectopic expression of the dac gene, alone or together with so and eya, results in ectopic eye formation (3, 4). Vertebrate homologs of ey (Pax6), so (Six), eya (Eya), and dac (DACH1) have been identified, and the human DACH1 (Dach1 in mice) gene encodes a protein composed of two highly conserved domains, dachshund domain 1 (DD1, also known as Box-N) with a predicted helix-turn-helix structure, and dachshund domain 2 (DD2, also known as Box-C). Altered expression of DACH1 has been reported in a variety of human tumors (5–9). DACH1 is expressed widely in normal epithelial tissues, and reduced DACH1 expression predicts poor outcome of breast and endometrial cancer patients (6, 9). DACH1 represses TGF-β signaling, reduces DNA synthesis, and reverses the tumorigenic phenotypes induced by the oncogenes such as ErbB2, Ras, Src, and Myc in human mammary cell lines (10, 11). Reintroduction of DACH1 into breast cancer cells inhibits cellular proliferation and migration/invasion in vitro and tumor initiation and metastasis in vivo (6, 11).

Crystallization of the human DACH1 Box-N revealed that DACH1 protein forms an α/β structure resembling a DNA binding motif found in the winged helix/forkhead subgroup of transcriptional factors (12). DACH1 is capable of binding both naked DNA and the chromatin DNA template through its Box-N domain, and the DNA binding is independent of its protein association with other DACH1-binding partners (13). A subsequent study using cyclic amplification and selection of targets (CAST) identified a DNA sequence that is specific for DACH1 binding (14). The DACH1 DNA binding sequence resembles a Forkhead protein binding site, and DACH1 competes with FOXM1 from being recruited to the promoter of FOXM1 target genes. The Forkhead Box (FOX) proteins are a family of evolutionarily conserved transcriptional regulators involved in diverse biological processes (15). Deregulation of FOX protein function in human tumorigenesis may occur by alteration in upstream regulators or genetic events such as

DRE, DACH1-response element; FOX, Forkhead Box; Luc, luciferase; TCERG1, transcription elongation regulator 1; WB, Western blotting.
mutations of the DNA binding domain (DBD), or translocations, which often disrupt the DBD. DACH1 inhibits FOXM1-mediated contact-independent growth, and DACH1 occupancy displaces FOXM1 in the context of local chromatin from the promoter of FOXM1-targeted genes including CDC25B, SKP2, and CDH1 (14).

Although the role of DACH1 in tumorigenesis has been demonstrated and DACH1-specific DNA binding has been identified, the molecular mechanisms through which DACH1 conveys trans-repression function are largely unknown. The current study was designed to characterize the molecular mechanisms governing DACH1 trans-repression at its cognate DNA binding site and to identify functional and biological interactions between DACH1 and FOX protein. We demonstrate that DACH1 functionally antagonizes FOXC2-mediated cellular migration. We identify the transcriptional co-integrator, TCERG1, as a rate-limiting regulator of DACH1 transcriptional activity.

**EXPERIMENTAL PROCEDURES**

**Cell Culture**—Human embryonic kidney 293T (HEK 293T), HeLa, and MCF-7 cells were maintained in DMEM containing 1% penicillin/streptomycin and supplemented with 10% fetal bovine serum (FBS). MCF-10A cells were cultured in DMEM/F12 (50:50) supplemented with 5% horse serum, 10% fetal bovine serum (FBS). MCF-10A cells were cultured in 1% penicillin/streptomycin and supplemented with 10% fetal bovine serum (FBS).

**Plasmids and Small Interfering RNA**—Human cDNA of DACH1 wild-type and mutants, including DNA binding domain (amino acids 183–293) deletion (ΔDBD), carboxy-terminal (C-ter) deletion mutant (amino acids 1–565) and C-ter (amino acids 566–706), were cloned into the p3X FLAG-CMV<sup>TM</sup>-10 (Sigma-Aldrich) vector. DACH1-responsive element (DRE)-Luc reporter were provided by Dr. R. Costa (17). The FOXC2 expression vector and FOXA luciferase reporter vector were formed following a protocol described previously (14).

**Transfection, Infection, and Gene Reporter Assays**—DNA transfection and luciferase assays were performed at room temperature using an Autolumat LB 953 (EG&G Berthold) as described previously (21). The transient transfection of HEK 293T cells with siRNA targeting human TCERG1 was described previously (19).

The MScV-IRES-GFP retrovirus vector expressing FOXC2 and the vector Ps-v-ψ-E-MLV that provides ecotropic packaging helper function and infection methods were described previously (22). Retroviruses were prepared by transient co-transfection of plasmid DNA using calcium phosphate precipitation. The retroviral supernatants were harvested 48 h after transfection and filtered through a 0.45-µm filter. Immortalized mammary epithelial MCF-10A cells were incubated with retroviral supernatants in the presence of 8 µg/ml hexadimethrine bromide for 24 h, cultured for a further 48 h, and subjected to fluorescence-activated cell sorting (FACS) (FACStar Plus; BD Biosciences) to select for cells expressing GFP. GFP-positive cells were used for subsequent analysis.

**Cellular Migration Assay**—Briefly, 2.5 × 10<sup>4</sup> cells were seeded on an 8-µm pore size Transwell filter insert (Corning, Inc., Corning, NY) coated with ECM (1:7.5) (Sigma). After 6 h of incubation at 37 °C and 5% CO<sub>2</sub>, cells adherent to the upper surface of the filter were removed using a cotton applicator. Cells were stained with 0.4% crystal violet dissolved in methanol, and the numbers of cells on the bottom were counted.

**Three-dimensional Invasion Assay**—100 µl of 1.67 mg/ml rat tail collagen type I (BD Biosciences) was pipetted in the top chamber of a 24-well 8-µm Transwell (Corning). The Transwell was incubated at 37 °C overnight to allow the collagen to solidify. 3 × 10<sup>4</sup> cells were then seeded on the bottom of the Transwell membrane and allowed to attach for 4 h. Serum-free growth medium was placed in the bottom chamber, whereas 5% serum was used as a chemoattractant in the growth medium of the upper chamber. The cells were then chemotactically across the filter through the collagen above for 3 days. Cells were fixed in 4% formaldehyde and permeabilized with 0.2% Triton X-100 in PBS then stained with 40 µg/µl propidium iodide for 2 h. Fluorescence was analyzed by confocal z-sections (1 section every 4 µm) at 10× magnification from the bottom of the filter. Three-dimensional reconstructions of the propidium iodide-stained cells were done using Carl Zeiss Zen software (2007 Light Edition).

**Immunoprecipitation (IP), Western Blotting (WB), and Chromatin Immunoprecipitation (ChIP) Analysis**—IP and WB assays were performed in HEK 293T cells as indicated. Cells were pelleted and lysed in buffer (50 mM HEPES, pH 7.2, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1% Tween 20) supplemented with protease inhibitor mixture (Roche Diagnostics). Antibodies used for IP and WB were: anti-T7; (Bethyl Laboratories, Montgomery, TX), anti-FLAG (M2 clone; Sigma), anti-FOXM1 (C20; Santa Cruz), and anti-DACH1 (Abcam; Cambridge, MA). ChIP analysis was performed following a protocol described previously (14).
DACH1 Repression of Forkhead Protein Function

**RESULTS**

*DACH1 Encodes a Heterologous Transcriptional Repressor*—A DACH1-specific DNA binding sequence was recently identified (14). To characterize the biological significance of DACH1 DNA binding further, we cloned a 13-bp DACH1 binding sequence, designated as DRE, into pGL3 luciferase reporter vectors pGL3-SV40 and pGL3-basic (Promega). Transfection of DRE-Luc in HeLa cells demonstrated that DACH1 conveys transcriptional repression through the DNA binding sequence, independent of sequence orientation (Fig. 1, A and B). A multicenter DRE was cloned upstream of either the E4 TATA minimal or β-globin promoter to determine whether the transcriptional repression by DACH1 was promoter-selective. DACH1 repressed DRE-Luc transcriptional activity when linked to the E4 TATA box or the β-globin TATA box (Fig. 1C and data not shown). To determine whether DACH1 conveys heterologous transcriptional repression function, DACH1 was expressed as a Gal4 fusion protein (Gal4-DACH1) and analyzed using the upstream activator sequence linked to the minimal TATA box ([(UAS)$_5$-E1B-TATA-Luc]). DACH1 expression conveyed trans-repression function independently of its DNA binding sequence (Fig. 1D). Thus, DACH1 is capable of repressing transcriptional activity in a DNA sequence-specific manner.

*Modeling Studies of DACH1 and FOX Protein Binding with DNA*—The crystal structure of the DBD of human FOXM1 complexed with DNA duplex (21 nucleotides long) is available in the Protein Data Bank (code 3G73). The structure of the complex of the DBD FOXM1 with DNA. The sequence of the human DACH1 (NCBI sequence ID NP_542937) was searched against the NCBI Protein Data Bank structure data base, we found that this sequence has 100% homology with that of the x-ray crystal structure of the retinal determination protein Dachshund (Protein Data Bank code 1L8R) (5). The three-dimensional structure of DACH1 (amino acids 3–101) was used to dock into the major groove of a segment of DNA double helical structure. The whole complex was energy-minimized using the program AMBERB8 Molecular Stimulation and Modeling software to refine the interactions between the human DACH1 protein and DNA.

*Identification of DACH1-associated Protein by Mass Spectrometry*—HEK 293T cells were transiently transfected with expression vector encoding FLAG-tagged DACH1. Total protein extracts were prepared using lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) supplemented with protease inhibitor mixture (Roche Diagnostics). The manufacturer’s instructions were followed to prepare the anti-FLAG antibody affinity column and washing buffer (Technical Bulletin no. MB-925, Sigma-Aldrich). The DACH1 complex was eluted from the column with TBS buffer containing 3×FLAG peptide and concentrated with P10 (10-kDa cutoff column; Millipore) and loaded onto 8% SDS-polyacrylamide gel. The silver-stained bands were excised from SDS-polyacrylamide gels and completely destained with 200 mM ammonium bicarbonate. These gel pieces were treated with 10 mM DTT in 0.1 M ammonium bicarbonate for protein reduction. Free cysteine residues were alkylated with freshly made 55 mM iodoacetamide in 0.1 M ammonium bicarbonate. Proteins were digested by the addition of 25 ng/μl sequence-grade modified trypsin (Promega) in ammonium bicarbonate buffer for 16 h at 30 °C with agitation. The digestion products were cleaned and concentrated using micro-C18 ZipTip (Millipore) mixed with 0.5 μl of 10 mg/ml α-cyano-4-hydroxysuccinamic acid in 50% acetonitrile, 0.1% (v/v) trifluoroacetic acid, and applied onto a MALDI plate.
binding. A prediction model of the DBD of DACH1 was generated (Fig. 2A). For DACH1 and FOXM1, the HLH motifs are shown by cyan ribbon spirals, and the rest of the ribbon structures for both complexes are shown in magenta. Despite these differences in secondary structures shown on the top and the left side of the proteins; the DNA interaction helix-loop-helix motifs (cyan ribbon spirals) are similar in orientation between DACH1 and FOXM1.

**DACH1 Attenuates Forkhead-dependent Transcriptional Activity**—To investigate the possibility that DACH1 may regulate Forkhead trans-activation, luciferase reporter assays were conducted with several Forkhead family proteins, including FOXM1, FOXO1 (FKHR), and FOXC2. FOXM1 induced the DRE6-Luc activity \( \times 12 \)-fold (Fig. 2C). DACH1 repressed activity of a reporter containing six copies of the FOXM1 binding consensus sequence (FoxA)\(_6\)-Luc by \( \times 60\% \) (Fig. 2D). Expression of the FOX protein, FOXO1, activated the (DRE)\(_6\)-Luc \( \times 11\)-fold (Fig. 2E). FOXC2 induction of (DRE)\(_6\)-Luc was also observed (Fig. 2F).

These studies suggested that DACH1 may function to repress FOX protein-dependent gene expression via competition with cognate DNA binding sites. Prior to conducting...
promoter occupancy studies to prove this, we examined the relative abundance of DACH1 and FOXM1 in cell lines. DACH1 was readily detected in HEK 293T and HeLa cells by WB (data not shown). FOXM1 was detectable in each cell line. DACH1 abundance was regulated by serum addition with a nadir at 4–6 h (~8-fold variation in abundance) (data not shown). FOXM1 induced activity of the consensus DRE in MCF-7 cells, and this activity was repressed by DACH1 in a dose-dependent manner (Fig. 3A). Luciferase reporter assay was conducted in HEK 293T cells transduced with either shRNA for DACH1 or control, showing enhanced FOX transactivation (Fig. 3B). We have previously shown that overexpression of DACH1 competes with FOXM1 for DNA binding (14). We further confirmed this observation by reducing the endogenous levels of DACH1 in HEK 293T. The amount of FOXM1 recruited to the promoter of its target genes was increased upon reduction of DACH1 expression (Fig. 3C).

DACH1 Inhibits FOXC2-induced Cellular Migration—It has been shown previously that FOXC2 is overexpressed in breast cancers and high levels of FOXC2 correlate with aggressiveness of ductal breast carcinoma (18). MCF-10A cells overexpressing FOXC2 enhanced Transwell migration in a Boyden chamber ~9-fold (Fig. 4A). Retroviral transduction of FOXC2-expressing MCF-10A cells increased cell invasion in a three-dimensional invasion assay. Introduction of DACH1 into these cells abolished the FOXC2-induced cellular migration and invasion (Fig. 4B), suggesting a functional repression of FOXC2 by DACH1.

TCEG1 Is a DACH1 Transcriptional Co-integrator—To determine, at a high level of resolution, the molecular mechanisms by which DACH1 conducts transcriptional repression, a proteomic approach was used to identify can-
DACH1 Repression of Forkhead Protein Function

FIGURE 5. DACH1 binds the co-integrator TCERG1. A, experimental approach used for identification of DACH1-binding proteins. B, HEK 293T cells transiently transfected with FLAG-DACH1-expressing vector. 50 mg of whole cell lysates were subjected to an immune-affinity column preloaded with a 1 ml slurry of M2 agarose beads (Sigma). The proteins associated with agarose beads were eluted with buffer containing 100 μg FLAG peptide. Western blotting was conducted of the eluted DACH1 using the anti-FLAG antibody (Sigma). C, eluted proteins separated on 4–20% gradient SDS-PAGE using a silver-stained gel. D, peptide sequence aligning to TCERG1. E, IP-Western blotting to determine DACH1 and TCERG1 binding. Expression vector for DACH1 (FLAG-tagged) and a series of TCERG1 deletion mutants (T7-tagged) were used to transfect HEK 293T cells. IP was conducted with anti-FLAG antibody for DACH1 and Western blotting with T7 antibody for TCERG1. F, schematic representation of the TCERG1 expression vectors and observed DACH1 binding ability. G, co-immunoprecipitation assays performed by incubating GST fusion proteins of TCERG1 with FLAG-DACH1 protein expressed in HEK 293T cells. IP was conducted using anti-FLAG (M2) antibody followed by Western blotting using GST antibody to detect mutants of TCERG1.

DACH1-binding co-regulator proteins (Fig. 5A). DACH1 protein complexes were prepared from HEK 293T cells transiently transfected with FLAG-DACH1-expressing vector (Fig. 5B). DACH1-associated proteins were resolved on a 4–10% Tris–HCl gel and silver-stained (Fig. 5C). The proteins recovered from the gel were subjected to in-gel tryptic digestion and sequential MS/MS. One of the excised bands corresponding to 145 kDa was identified as TCERG1 (Fig. 5D).

To determine the domain of physical interaction between DACH1 and TCERG1, FLAG-DACH1 was co-expressed with T7-tagged wild-type and a series of deletion mutants of TCERG1. IP was conducted with anti-FLAG with sequential WB for the T7 tag of TCERG1 (Fig. 5E). The upper panel shows the WB of the cell extracts, and the lower panel shows the IP-WB. IP-WB analysis demonstrated the co-precipitation of TCERG1 with DACH1. The WW domain binds to the SF1 splicing factor (24). Deletion of all three WW domains did not affect DACH1 binding (Fig. 5, E and F); however, deletion of the carboxyl terminus (TCERG1, amino acids 1–662) abrogated DACH1 binding (Fig. 5, E and F). Sequential carboxy-terminal deletion of the FF domain abrogated DACH1 binding upon deletion of FF2 (construct 1–787 versus 1–715). Thus, DACH1 binding to the TCERG1 co-integrator protein requires the FF2 domain. Next, we determined whether the FF2 domain of TCERG1 is sufficient for binding to DACH1. We performed immunoprecipitation assays by incubating cell extracts prepared from HEK 293T cells transfected with FLAG-DACH1 plasmid with the FF2 domain expressed in bacteria as a GST fusion protein (25). The FF2 domain that was required for DACH1 binding was also sufficient for DACH1 binding (Fig. 5G). TCERG1 is a promoter-specific transcriptional co-regulator of human immunodeficiency virus (HIV) Tat gene (26, 27). We therefore sought to determine whether TCERG1 functions as a co-regulator of DACH1. HEK 293T cells were
DACH1 Repression of Forkhead Protein Function

FIGURE 6. TCERG1 is required for DACH1 trans-repression. A, HEK 293T cells transfected with DACH1 and TCERG1 mutants together with (DRE)₆-Luc. The carboxy-terminal deletion of TCERG1, which does not bind DACH1, is defective for repression. B, HEK 293T cells transfected with TCERG1 siRNA and control for 48 h followed by transfection with indicated luciferase reporter plasmids. C, HEK 293T cells transfected with TCERG1 and Gal4-DACH1 or control vector together with Gal4 reporter, showing that TCERG1 enhanced DACH1-mediated transcriptional repression.

transfected with (DRE)₆-Luc reporter and a DACH1 expression vector. TCERG1 expression enhanced DACH1 transcriptional repression (Fig. 6A). We next determined the domain of TCERG1 that is required to enhance DACH1 trans-repression. The carboxy-terminal deletion mutant (amino acids 1–715), which does not bind to DACH1, was defective in enhancing DACH1-mediated trans-repression function (Fig. 6A). TCERG1 enhancement of DACH1 repression was further confirmed by knockdown of TCERG1 with siRNA, showing that reduced TCERG1 expression reversed DACH1 repression in the reporter assay (Fig. 6B). The synergistic repression of TCERG1 and Gal4-DACH1 on (UAS)₅-E1B-TATA-Luc reporter suggested that TCERG1 enhances DACH1-mediated trans-repression independent of its DNA binding (Fig. 6C).

Carboxyl Terminus of DACH1 Exhibits Trans-repression through Binding TCERG1—To identify the domain of DACH1 required for TCERG1 binding, IP–WB was conducted. DACH1 mutants were assessed using anti-FLAG antibody with sequential blotting to the T7 tag of TCERG1 (Fig. 7A). Deletion of the DACH1 carboxy-terminal (amino acids 566–706) residues abrogated binding to TCERG1 (Fig. 7A). Deletion of the DNA binding domain (ΔDBD) did not affect DACH1 binding to TCERG1 (data not shown).

The ΔDBD mutant of DACH1 was capable of binding TCERG1 and showed a dominant negative effect on DACH1 repression (Fig. 7C). The dominant negative effect may be due to competition with wild-type DACH1 through its carboxy-terminal for a limited TCERG1 pool in the cell. Consistent with this model, the C-ter of DACH1, which is sufficient for TCERG1 binding by itself, exhibited a dominant negative effect on the DRE reporter gene activity (Fig. 7C). Therefore, we conclude that the carboxy terminus of DACH1 conveys a trans-repression function through binding TCERG1. Consistent with the importance of the DACH1 binding to TCERG1 via its C terminus, the deletion of the DACH1 carboxy terminus (ΔC) impaired DACH1 trans-repression function and ΔC exhibited strong dominant negative effect on full-length DACH1 in gene reporter assays (Fig. 7D).

DISCUSSION

This study provides the first mechanistic evidence that DACH1 is a transcription factor (14) that represses gene transcription through binding transcription elongation regulator 1 (TCERG1, also known as CA150 or TAF2S). TCERG1 is a nuclear protein associated with the RNA polymerase II holoenzyme. FOX proteins activate gene transcription, and DACH1 competes with FOX protein in the context of local chromatin to repress gene expression. Decreased DACH1 expression and overexpression of oncogenic FOX protein could lead to deregulation of a subset of genes required for tumorigenesis.

DACH1 regulates gene expression by complexing with DNA-binding transcription factors, including Six, Jun, and Smad4 (6, 10, 28, 29). Analysis of the components of the RDGN has implicated dac in cell fate specification. Six6−/− mutant mice present hypoplastic pituitary glands with a variable penetrance and retinal hypoplasia with decreased ganglion cell layer cell number. Mammalian 2-hybrid experiments suggest that Six6 interacts with DACH1, whereas molecular mapping studies reveal co-precipitation of DACH1 with NCoR, HDAC3, and Sin3a/b (28). These molecular interactions are consistent with studies by Ikeda et al., which suggest that Eya interacts with Six6 in mammalian two-hybrid, but does not interact with DACH1 (13). DACH1, however, is capable of transactivating in the presence of an Eya fusion protein, suggesting that the CREB-binding protein, CBP, mediates the interaction between Eya and DACH1. The functional significance of CBP versus TCERG1 in DACH1-mediated function remains to be determined. DACH1 is also known to inhibit TGF-β signaling in ovarian cancer. Future studies will address whether loss of DACH1 in cancers correlates with increased expression of oncogenes, whose promoter have DACH1 binding site(s).

DACH1 conveys transcriptional repression when linked to a heterologous DNA binding domain. Proteomic analysis identified the co-integrator protein TCERG1 as a candidate mediator of DACH1 transcriptional repression. TCERG1 is a
promoter-specific transcription co-regulator of HIV Tat gene (26, 27). TCERG1 expression enhanced DACH1-mediated trans-repression. It has been reported previously that the carboxyl-terminal and amino-terminal halves of TCERG1, containing FF repeats and WW domains, respectively, are required for efficient repression of the α4-integrin gene expression (24). We included two mutants of TCERG1 representing the FF domain (FF2–6) deletion and amino-terminal deletion (591–1098) in DACH1 trans-repression assays. The carboxyl-terminal deletion of TCERG1 (1–715) defective for DACH1 binding failed to enhance DACH1 repression, although the WW domain deletion has no effect on TCERG1 function as a co-repressor of DACH1. Through multiple WW domains in its amino terminus, TCERG1 associates with splicing factor 1 (SF1) (24), a protein that functions in the assembly of a pre-RNA splicing complex. We failed to observe synergistic repression of SF1 (24) in DACH1-transfected cells to those in vector control-transfected cells. The data are shown as mean ± S.E. (error bars) from at least two separate experiments with triplicate samples each. E, schematic representation of proposed model by which DACH1 and FOXM1 compete to regulate gene expression.

**REFERENCES**

1. Wawersik, S., and Maas, R. L. (2000) *Hum. Mol. Genet.* 9, 917–925
2. Mardon, G., Solomon, N. M., and Rubin, G. M. (1994) *Development* 120, 3473–3486
3. Chen, R., Amoui, M., Zhang, Z., and Mardon, G. (1997) *Cell* 91, 893–903
4. Shen, W., and Mardon, G. (1997) *Development* 124, 45–52
5. Sunde, J. S., Donninger, H., Wu, K., Johnson, M. E., Pestell, R. G., Rose, G. S., Mok, S. C., Brady, J., Bonome, T., and Birrer, M. J. (2006) *Cancer Res.* 66, 8404–8412
6. Wu, K., Li, A., Rao, M., Liu, M., Dailey, V., Yang, Y., Di Vizio, D., Wang, C., Lisanti, M. P., Sauter, G., Russell, R. G., Cvekl, A., and Pestell, R. G. (2006) *Mol. Cell. Biol.* 26, 7116–7129
7. Dalgin, G. S., Drever, M., Williams, T., King, T., Delisi, C., and Liu, L. S. (2008) *J. Urol.* 180, 1126–1130
8. Yamada, Y., Arai, T., Gotoda, T., Taniguchi, H., Oda, I., Shirao, K., Shimada, Y., Hamaguchi, T., Kato, K., Hamano, T., Koizumi, F., Tamura, T., Saito, D., Shimoda, T., Saka, M., Fukagawa, T., Kato, H., Sano, T., Sasako, M., and Nishio, K. (2008) *Cancer Sci.* 99, 2193–2199
9. Nan, F., Liu, Q., Zhou, J., Cheng, L., Popov, V. M., Wei, S., Kong, B., Pestell, R. G., Lisanti, M. P., Jiang, J., and Wang, C. (2009) *Cancer Biol. Ther.* 8, 1534–1539
10. Wu, K., Liu, M., Li, A., Donninger, H., Rao, M., Jiao, X., Lisanti, M. P.,...
11. Wu, K., Katiyar, S., Li, A., Liu, M., Ju, X., Popov, V. M., jiao, X., Lisanti, M. P., Casola, A., and Pestell, R. G. (2008) Proc. Natl. Acad. Sci. U.S.A. 105, 6924–6929
12. Kim, S. S., Zhang, R. G., Braunstein, S. E., Joachimiak, A., Cvekl, A., and Hegde, R. S. (2002) Structure 10, 787–795
13. Ikeda, K., Watanabe, Y., Ohto, H., and Kawakami, K. (2002) Mol. Cell. Biol. 22, 6759–6766
14. Zhou, J., Wang, C., Wang, Z., Dampier, W., Wu, K., Casimiro, M. C., Chepelev, I., Popov, V. M., Quong, A., Tozeren, A., Zhao, K., Lisanti, M. P., and Pestell, R. G. (2010) Proc. Natl. Acad. Sci. U.S.A. 107, 6864–6869
15. Hannenhalli, S., and Kaestner, K. H. (2009) Nat. Rev. Genet. 10, 233–240
16. Sánchez-Alvarez, M., Goldstrohm, A. C., Garcia-Blanco, M. A., and Suté, C. (2006) Mol. Cell. Biol. 26, 4998–5014
17. Al-Kuraya, K., Searl, P., Torhorst, J., Tapia, C., Zaharieva, B., Novotny, H., Spichtin, H., Maurer, R., Mirlacher, M., Köchli, O., Zubr, M., Dieterich, H., Mross, F., Wilber, K., Simon, R., and Sauter, G. (2004) Cancer Res. 64, 8534–8540
18. Mani, S. A., Yang, J., Brooks, M., Schwaninger, G., Zhou, A., Miura, N., Kutok, J. L., Hartwell, K., Richardson, A. L., and Weinberg, R. A. (2007) Proc. Natl. Acad. Sci. U.S.A. 104, 10069–10074
19. Pearson, J. L., Robinson, T. J., Muñoz, M. J., Kornblith, A. R., and Garcia-Blanco, M. A. (2008) J. Biol. Chem. 283, 7949–7961
20. Wang, C., Fu, M., D’Amico, M., Albanese, C., Zhou, J. N., Brownlee, M., Lisanti, M. P., Chatterjee, V. K., Lazar, M. A., and Pestell, R. G. (2001) Mol. Cell. Biol. 21, 3057–3070
21. Wang, C., Pattabiraman, N., Zhou, J. N., Fu, M., Sakamaki, T., Albanese, C., Li, Z., Wu, K., Hults, J., Neumeister, P., Novikoff, P. M., Brownlee, M., Scherer, P. E., Jones, J. G., Whitney, K. D., Donehower, L. A., Harris, E. L., Rohan, T., Johns, D. C., and Pestell, R. G. (2003) Mol. Cell. Biol. 23, 6159–6173
22. Neumeister, P., Pixley, F. J., Xiong, Y., Xie, H., Wu, K., Ashton, A., Cammer, M., Chan, A., Symons, M., Stanley, E. R., and Pestell, R. G. (2003) Mol. Biol. Cell 14, 2005–2015
23. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., and Ferrin, T. E. (2004) J. Comput. Chem. 25, 1605–1612
24. Goldstrohm, A. C., Albrecht, T. R., Suté, C., Bedford, M. T., and Garcia-Blanco, M. A. (2001) Mol. Cell. Biol. 21, 7617–7628
25. Carty, S. M., Goldstrohm, A. C., Suté, C., Garcia-Blanco, M. A., and Greenleaf, A. L. (2000) Proc. Natl. Acad. Sci. U.S.A. 97, 9015–9020
26. Suté, C., Hayashi, T., Liu, Y., Lane, W. S., Young, R. A., and Garcia-Blanco, M. A. (1997) Mol. Cell. Biol. 17, 6029–6039
27. Suté, C., and Garcia-Blanco, M. A. (1999) Mol. Cell. Biol. 19, 4719–4728
28. Wu, K., Yang, Y., Wang, C., Davoli, M. A., D’Amico, M., Li, A., Cvekl,ova, K., Kozmik, Z., Lisanti, M. P., Russell, R. G., Cvekl, A., and Pestell, R. G. (2003) J. Biol. Chem. 278, 51673–51684
29. Li, X., Perissi, V., Liu, F., Rose, D. W., and Rosenfeld, M. G. (2002) Science 297, 1180–1183